Objective: To review the various mechanisms of glucocorticoid action and the ability of these agents to induce osteoporosis and growth deficits.
Introduction
Glucocorticoids (GCs) are produced and secreted by the adrenal cortex and play an important role in several organs and systems of the body, taking part in physiological regulation and adaptation to stress events and modulating the range of host defenses. Circulating GC levels are regulated by adjustments in the hypothalamic-pituitary-
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Teresinha Lermen Donatti, 1 Vera Hermina Kalika Koch, 2 Liliam Takayama, 3 Rosa Maria Rodrigues Pereira 4 adrenal (HPA) axis, which are influenced by such factors as circadian rhythm, stress, and negative feedback, the latter provided by the effects of GCs themselves on the glucocorticoid receptors (GRs) expressed in the hypothalamus and pituitary gland. 1 Connections between the neuroendocrine and immune system provide a finely tuned regulatory system that plays a highly important role in health and well-being. Disturbances at any level of the HPA axis or in GC activity lead to unbalance in this system, increasing host susceptibility to infectious, inflammatory, and autoimmune disease. 2 One important mechanism whereby activation of the HPA axis regulates immune response and severity of expression of the resulting disease is mediated by the effects of GCs at the molecular level, through their interactions with GRs. 1 The endpoint of GC activity on the body's tissues is mediated by the GR (NR3C1), a member of the steroid and thyroid hormone receptor superfamily. Like the progesterone, androgen, and mineralocorticoid receptors, the GR is essentially a ligand-dependent transcription factor.
GCs circulate in plasma while bound to GC-binding globulins or albumin. GCs enter the cell through passive diffusion and, less importantly, by active cell transport mechanisms. 3 Cortisol and a variety of synthetic GC agonists can modulate carbohydrate, protein, and lipid metabolism and regulate immune, bone-metabolism, and cardiovascular function. 4 Cell response after GC exposure is due to several modulating factors, such as free hormone levels, the relative potency of the hormone, and the ability of the cell to receive and translate hormone-mediated signals.
The key modulators are GCs themselves, which promote a reduction in GR levels by a process known as homologous downregulation; this process decreases sensitivity and thus affords a measure of protection against the untoward effects of excessive GC activity. 1 
Glucocorticoids and the immune system
Among the various important actions of GCs on the body's tissues, those related to the immune system give them a key role in the therapeutic armamentarium against autoimmune conditions.
GCs regulate a broad variety of immune cell functions and immune mediator expression at the molecular level.
GCs modulate: expression of cytokines and cell adhesion molecules; traffic, maturation, and differentiation of immune system cells; expression of substances involved in molecular adhesion and cell migration; and production of proinflammatory mediators and other molecules involved in inflammation. They act chiefly on certain subgroups of T lymphocytes, suppressing T helper type I cell (Th1) function and encouraging eosinophil apoptosis. 3, 5, 6 By inhibiting the activity of transcription factor activator protein 1 (AP-1),
GCs block synthesis of the protein that breaks down the enzyme collagenase, which, in turn, is the number-one culprit behind connective tissue destruction in rheumatoid arthritis 6 ; and, by inhibiting NF-κB, they alter the production of cytokines that play an important role in the process of inflammation. 7 Another major effect of GCs is their antiproliferative and apoptotic action, both in cell cultures and in vivo. GC- 8, 11 This review will address the several effects of GCs that have the potential to interfere with growth and bone mineralization.
Glucocorticoids and their relationship with growth factors and bone metabolism

Glucocorticoids and growth hormone
Under physiological conditions, there is a positive correlation between the parameters that determine the amount of cortisol and growth hormone (GH) secreted over a 24-hour period, which suggests that both are closely related under physiological conditions. 12 Glucocorticoids: growth and bone mineralization -Donatti TL et al.
In the pituitary gland, GCs modulate GH gene expression and somatotropic axis response to several GH secretagogues, with various stimulating or inhibitory effects depending on species, length of treatment, and experimental setting (in vitro or in vivo). 13 GCs boost GH synthesis and release in vitro by activating GH gene transcription and upregulating GH-releasing hormone (GHRH) receptor expression. 14 Conversely, chronic administration of GCs in vivo inhibits GH secretion. 15 In vitro, prolonged exposure of rat somatotropes transfected with the mouse GH gene to dexamethasone in the presence of T 3 stimulated transcription of this gene. 16 These heterogeneous effects of GCs on GH release have been described by Soliman et al. 17 
Glucocorticoids and insulin-like growth factors
GC treatment reduces the biological activity of insulinlike growth factor 1 (IGF-1) 18 without decreasing its serum levels. 19 GCs are also believed to inhibit autocrine/paracrine IGF-1 synthesis and secretion, blocking transcription by reducing IGF-1 mRNA abundance. 20, 21 GC also inhibits bone growth by downregulating IGF-1, but not IGF-2, expression at the epiphyseal plate. 22, 23 GCs play a role in regulation of the most distal point of the GH-IGF axis, modulating expression or intracellular signaling of the IGF type 1 receptor. 24 
Glucocorticoids and insulin-like growth factorbinding proteins
IGF-1 binding protein (IGFBP-1) levels oscillate over a 24-hour period, with this variation almost perfectly superimposed on the circadian rhythm for cortisol. 25 Cortisol increases IGFBP-1 synthesis, partly by increasing transcription. 26 There is a negative correlation between morning IGFBP-2 concentrations and nocturnal cortisol secretion, and although cortisol has no direct influence on IGFBP-3 secretion, it appears to stimulate proteolysis of IGFBP-3. 25 When taken as a whole, increased IGFBP-1 levels, the increased number of fragments due to IGFBP-3 proteolysis, and decreased IGFBP-2 levels due to higher GC concentrations may decrease the bioavailability or even reduce the biological activity of insulin-like growth factors.
This, in turn, would stimulate increased GH secretion by blunting negative feedback at the hypothalamic/ pituitary level, making cortisol and GH secretion vary synchronously. 24 Reduced biological activity of IGF thus appears to be the determining event of this regulatory mechanism, which would produce increased GH secretion and, consequently, increase serum levels of peptides that are secreted in a GH-responsive manner -namely, IGF-1, IGFBP-3 and, possibly, IGFBP-5 and the acid-labile subunit. 24 
Glucocorticoids, gonadotropins, and puberty
Chronic use of GC blunts gonadotropin pulsatility.
Clinically, this effect translates into a retardation of the development of secondary sexual characteristics during puberty. 27 Both GC therapy and stress-induced increases in serum cortisol levels can reduce circulating testosterone levels in men. By decreasing ACTH secretion at the anterior pituitary,
GCs also decrease androgen synthesis and secretion by the adrenal glands. 28 Patients taking GCs during puberty can incur extreme delays in development of pubertal characteristics and in the pubertal growth spurt. Furthermore, sex steroids play a critical role in determining bone mass; 40 to 50% of total lifetime bone mass in women (and a slightly lower percentage in men) accumulates during puberty.
In addition to GH and IGF, estradiol and testosterone have effects of their own on bone mineralization. Therefore, retardation of the pubertal growth spurt or a lack of pubertal progression will reduce bone quality, the limits of which vary widely depending on the patient's overall condition. 29 
Glucocorticoids and calcium metabolism
The systemic effects of GCs on other structures 
Glucocorticoids and parathyroid hormone (PTH) metabolism
Bonadonna et al. 31 recently showed that chronic GC therapy induces a redistribution of spontaneous PTH secretory dynamics by reducing the amount of PTH released in a tonic fashion and increasing the amount released as pulses. This change could have primary or secondary effects on bone metabolism in patients undergoing GC treatment.
Direct action of glucocorticoids on bone cells
GCs inhibit replication of osteoblast-lineage cells, decrease production of pre-osteoblasts and osteoblasts, and induce apoptosis of mature osteoblasts and osteocytes.
Furthermore, GCs hinder stromal cell differentiation into the osteoblast lineage and reduce the rate of terminal osteoblast differentiation, thus reducing mature osteoblast counts. 28, 32 GCs also induce commitment of stromal cells to the adipocyte lineage, promoting adipogenesis at the expense of osteoblastogenesis. 32 GCs inhibit alkaline phosphatase activity and synthesis of type I collagen and bone proteins, such as osteocalcin, which are biomarkers of osteoblast activity. They also boost osteoclastogenesis, upregulating expression of the receptor activator of nuclear factor kappa-B ligand (RANKL) and downregulating expression of its soluble decoy receptor, osteoprotegerin, in osteoblast cells. They also increase expression of colony-stimulating factor 1, which induces osteoclastogenesis in the presence of RANKL. 15, 33, 34 The reduction in bone remodeling that develops during chronic GC therapy is thus mostly due to a direct effect of GCs on osteoblasts. 32, 35 Glucocorticoids and the local GH-IGF-IGFBP axis at the epiphyseal plate Myopathy and muscle weakness may also play a role in bone loss by reducing physical activity, which encourages bone mass formation through muscle contractions. 38, 39 The catabolic or antianabolic effects of GCs may partly account for their negative impact on growth rates.
The catch-up effect and bone mass recovery after discontinuation of glucocorticoid therapy or resolution of hypercortisolism GC-induced changes in growth and bone mineralization are fully reversible after treatment discontinuation, 9 as long as patients are provided favorable conditions for mineralization to occur.
Discontinuation of GC therapy is followed by a period of compensatory growth, 40 which is at least partially due to an intrinsic mechanism at the epiphyseal plate. 41 Compensatory growth occurs because decreased cell proliferation during GC treatment preserves the proliferative capacity of chondrocytes, slowing maturation of the epiphyseal plate.
After completion of treatment, the epiphyseal plate has not "aged" as far as it normally would; consequently, the growth rate may be increased. Duration of the growth period may extend beyond expected for age, a phenomenon known as catch-up growth. 41 GC-induced changes in bone mineralization are also reversible. 9 In a study of patients with Cushing syndrome, osteoblast activity (as measured by increased serum osteocalcin levels) returned to normal within 6 months of cure. 42 On long-term follow-up after normalization of cortisol levels, nearly all of these patients showed marked improvement in bone mineral density (BMD). 9, 38, [42] [43] [44] One of the main effects of GCs on bone is to decrease the rate of osteogenesis. Long-term follow-up of former Cushing disease patients by serial dual X-ray energy absorptiometry (DXA) suggests this change is reversible. 43 Recovery is due to preservation of the trabecular bone structure, which keeps intact the scaffolding onto which osteoblasts can produce new bone after discontinuation of GC treatment.
This finding is in stark contrast to the trabecular loss found in other forms of osteoporosis. 9, 38 After adverse factors are withdrawn, lost bone is gradually recovered over a period of approximately 10 years. 44 
Assessment of bone metabolism and mineralization
Biochemical markers of bone metabolism
Information on the metabolic activity of bone tissue can be obtained through measurement of blood and urine levels of the byproducts of bone cell activity. Multiple experiments over the past few years have focused on the ability to 
Imaging methods for assessment of bone mineralization
The most common method for measurement of BMD is DXA. DXA measures BMD in the axial and appendicular skeleton, and can thus be used to assess cancellous and cortical bone alike. 47 DXA is considered the diagnostic method of choice for measurement of bone mass; it is fast (5 to 20 minutes), accurate, and associated with only low-level radiation exposure (< 10 mrem). 48 Bone density scanning can detect bone mass reductions of < 5%, whereas radiography is only able to detect losses in excess of 30 to 50%. Due to changes in bone size and geometry during child growth and development, interpretation of DXA scans in children is challenging. Proper interpretation must take into account skeletal maturity, pubertal development, ethnicity, body weight, and height. 47 Bone mass is expressed as bone mineral content (BMC, measured in grams) and as BMD (measured in g/cm 2 ), both of which can be influenced by bone size. Several mathematical models have been developed for estimation of bone volume in an attempt to minimize bone size bias.
Authors have recommended that correction of total BMD for bone size be based on patient height and bone area.
Although there is no consensus on the best method for adjustment, bone age and stage of puberty should be taken into account when interpreting densitometric studies in pediatric patients. 47 Osteoporosis is a systemic skeletal condition characterized by low bone mass and increased susceptibility to fractures. It has historically been considered a disease of adults, but low bone mass is increasingly recognized as a pathological entity in childhood. Bearing in mind that over 90% of total lifetime bone mass is present at 18 years of age, bone mass accrual in childhood is the single main determinant of peak bone mass and fracture risk. 49 The increased risk of fractures due to low bone mass. 38 Bone mass peaks around the ages of 20-30 years. In healthy persons, genetic factors, physical activity, diet, body weight, and ethnicity are known determinants. 51 Optimal bone mass accrual requires adequate nutrition, physical exercise (normal mobility), normal progression of puberty, bones in responsive conditions and an intact GH-IGF-1 axis. As noted above, most of these factors are affected or limited by chronic illness and GC therapy. Nevertheless, bearing these factors in mind may help implement useful interventions to mitigate, if not eliminate, the negative effects of chronic illness and GC use. 49 Standards have been developed for adult patients, 52 but current data are not sufficient for proper development of evidence-based guidelines for the prevention and management of GC-induced bone loss in childhood. Within this context, seeking to provide tools that can be used to minimize the effects of GC use on growth and bone mineralization, we will adapt the proposed interventions of a recent review 49 -which take into account the various issues associated with assessment of BMD in a growing skeleton -and address the effects of chronic illness and GC therapy on a variety of parameters, including bone itself, growth, puberty, diet, physical activity, and vitamin D levels.
Interventions
Glucocorticoids
The lowest effective dose of GCs should be used to achieve disease control, and weaning as early as possible -as soon as disease activity is no longer detectable -should be a treatment goal.
Local rather than systemic administration of corticosteroids (such as use of inhaled corticosteroids by children with asthma) may afford a measure of protection against bone damage. 49
Nutrition
Recent reviews of the influence of diet and nutritional status during childhood and adolescence on bone quality later in life are available. 53, 54 Attempts should be made to ensure a balanced diet providing adequate calorie, vitamin, and protein intake, which is often compromised in the setting of chronic illness, to avoid deterioration of nutritional status and negative consequences on growth and bone mineralization.
Exercise and mobility
Children and adolescents living with chronic illness are also prone to reduced mobility, which leads to poor bone mineral accrual. 49 Any type of physical activity is adequate, as long as it patients engage in it for a minimum of 1 hour three times a week. 55 Adequate physical activities should be encouraged whenever possible, as a means of improving the integrity of bone mechanics and thus enabling patients to bear the intermittent and unpredictable ill effects of GC use. Even though GC use will invariably lead to bone damage, the risk of fracture is decreased by physical activity, as mechanically stronger structures incur less damage.
Calcium and vitamin D
Several authors have shown that when calcium and vitamin D supplementation is added to prolonged GC therapy, its negative effects on bone fail to materialize 56, 57 or are mitigated. 58, 59 It has thus been suggested that early calcium and vitamin 
Puberty
Pubertal staging should be carefully monitored during prolonged GC therapy due to the well-established risk of hypogonadism. 27, 28 Although no large prospective studies have been conducted in patients with hypercortisolism, add-on therapy, such as sex hormone replacement therapy in male or female patients with hypogonadism, may be beneficial. 9, 38 Puberty should be induced or maintained with gonadal hormone therapy whenever a delay in pubertal development is detected. This approach makes it possible for adequate peak bone mass to be achieved and thus helps ensure adequate bone mass in adulthood. Intermittent hormone replacement therapy after puberty should be considered during periods of intermittent steroid therapy. 49 In patients with inflammatory bowel disease, estrogens should be administered transdermally to ensure consistent absorption. Boys may receive intramuscular, transdermal, or subcutaneous testosterone as required. 49 New data on the use of anabolic agents (PTH and GH)
in GC-induced osteoporosis are encouraging, but further standardization is required. 38, 63, 64 Specific measures: the role of bisphosphonates Some studies have reported that bisphosphonates are safe, effective, and well-tolerated for the prevention 65 and treatment 66 of GC-induced osteopenia and osteoporosis in children and adolescents. However, bisphosphonate therapy in the pediatric setting remains controversial, as data on long-term effects is lacking; hence, many experts recommend that use of these agents be limited to children with recurrent extremity fractures, symptomatic vertebral collapse, and significantly reduced bone mass, particularly when associated with aggravating factors such as immobility. 67 Current data are insufficient to support routine use of bisphosphonates to treat reduced bone mass alone in children. Further research is required to define appropriate indications for bisphosphonate therapy and to determine the optimal agent, dose, and duration of treatment in pediatric patients. 67 
Conclusions
The changes in growth and bone mineralization that take place in patients on long-term GC therapy at supraphysiological doses can be prevented with an adequate diet and calcium and vitamin D supplementation, 58, 59 physical exercise (enough to ensure normal mobility), and therapy directed at preserving the normal progression of puberty and maintaining the integrity of the GH-IGF-1 axis. 49 Should these changes occur, both the altered linear growth and the low bone mass associated with GC use are reversible after discontinuation of treatment; gradual but complete recovery of bone mass is achieved within approximately 10 years. 9, 38, [40] [41] [42] [43] [44] During this recovery period, however, patients with subnormal bone mass are at a high risk of fractures. One priority in caring for these patients should be the implementation of measures to speed up improvement of bone mineral density and prevent additional bone loss.
Therefore, these risks must be continuously assessed and detected in all patients receiving long-term GC therapy by means of clinical monitoring, assessment of dietary habits and physical activity, and serial DXA scanning. 9, 38 
